NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 37,272 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $22.01, for a total transaction of $820,356.72. Following the transaction, the chief executive officer now directly owns 776,862 shares of the company’s stock, valued at approximately $17,098,732.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Wednesday, September 13th, Asaf Danziger sold 35,500 shares of NovoCure Limited stock. The stock was sold at an average price of $22.01, for a total transaction of $781,355.00.
  • On Tuesday, July 11th, Asaf Danziger sold 7,383 shares of NovoCure Limited stock. The stock was sold at an average price of $19.95, for a total transaction of $147,290.85.
  • On Monday, July 10th, Asaf Danziger sold 274,359 shares of NovoCure Limited stock. The stock was sold at an average price of $18.07, for a total transaction of $4,957,667.13.
  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total transaction of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total transaction of $2,904,903.32.
  • On Monday, June 19th, Asaf Danziger sold 124,720 shares of NovoCure Limited stock. The stock was sold at an average price of $15.51, for a total transaction of $1,934,407.20.

Shares of NovoCure Limited (NASDAQ NVCR) opened at 20.65 on Friday. The stock has a 50 day moving average of $19.67 and a 200 day moving average of $14.42. The firm’s market cap is $1.84 billion. NovoCure Limited has a 52-week low of $5.95 and a 52-week high of $22.30.

NovoCure Limited (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The business had revenue of $38.38 million for the quarter, compared to the consensus estimate of $42.20 million. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. Equities analysts predict that NovoCure Limited will post ($0.77) EPS for the current fiscal year.

WARNING: “Asaf Danziger Sells 37,272 Shares of NovoCure Limited (NVCR) Stock” was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/17/asaf-danziger-sells-37272-shares-of-novocure-limited-nvcr-stock.html.

NVCR has been the subject of several recent research reports. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Wells Fargo & Company raised shares of NovoCure Limited from a “market perform” rating to an “outperform” rating and set a $15.00 price objective for the company in a research report on Wednesday, May 24th. BidaskClub raised shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 31st. Mizuho initiated coverage on shares of NovoCure Limited in a research report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $19.00 price objective (up previously from $18.00) on shares of NovoCure Limited in a research report on Monday, July 17th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. NovoCure Limited currently has a consensus rating of “Buy” and a consensus price target of $20.00.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can raised its position in NovoCure Limited by 1,919.7% during the second quarter. Bank of Montreal Can now owns 7,069 shares of the medical equipment provider’s stock valued at $122,000 after acquiring an additional 6,719 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in NovoCure Limited by 792.5% during the second quarter. BNP Paribas Arbitrage SA now owns 7,229 shares of the medical equipment provider’s stock valued at $125,000 after acquiring an additional 6,419 shares in the last quarter. Nisa Investment Advisors LLC bought a new position in NovoCure Limited during the second quarter valued at approximately $126,000. Fox Run Management L.L.C. bought a new position in NovoCure Limited during the second quarter valued at approximately $225,000. Finally, TIAA FSB bought a new position in NovoCure Limited during the second quarter valued at approximately $238,000. 36.84% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.